%A Yang,Ju %A Yan,Jing %A Liu,Baorui %D 2018 %J Frontiers in Immunology %C %F %G English %K VEGF,tumor,Angiogenesis,immune,T cells %Q %R 10.3389/fimmu.2018.00978 %W %L %M %P %7 %8 2018-May-03 %9 Mini Review %# %! Targeting VEGF/VEGFR to modulate antitumor immunity %* %< %T Targeting VEGF/VEGFR to Modulate Antitumor Immunity %U https://www.frontiersin.org/articles/10.3389/fimmu.2018.00978 %V 9 %0 JOURNAL ARTICLE %@ 1664-3224 %X In addition to the crucial role in promoting the growth of tumor vessels, vascular endothelial growth factor (VEGF) is also immunosuppressive. VEGF can inhibit the function of T cells, increase the recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and hinder the differentiation and activation of dendritic cells (DCs). Recent studies have investigated the role of antiangiogenic agents in antitumor immunity, especially in recent 3 years. Therefore, it is necessary to update the role of targeting VEGF/VEGFR in antitumor immunity. In this review, we focus on the latest clinical and preclinical findings on the modulatory role of antiangiogenic agents targeting VEGF/VEGFR in immune cells, including effector T cells, Tregs, MDSCs, DCs, tumor-associated macrophages, and mast cells. Our review will be potentially helpful for the development of combinations of angiogenesis inhibitors with immunological modulators.